1. Home
  2. MDWD vs KEQU Comparison

MDWD vs KEQU Comparison

Compare MDWD & KEQU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • KEQU
  • Stock Information
  • Founded
  • MDWD 2000
  • KEQU 1906
  • Country
  • MDWD Israel
  • KEQU United States
  • Employees
  • MDWD N/A
  • KEQU N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • KEQU Medical Specialities
  • Sector
  • MDWD Health Care
  • KEQU Industrials
  • Exchange
  • MDWD Nasdaq
  • KEQU Nasdaq
  • Market Cap
  • MDWD 184.8M
  • KEQU 183.3M
  • IPO Year
  • MDWD 2014
  • KEQU N/A
  • Fundamental
  • Price
  • MDWD $19.83
  • KEQU $60.94
  • Analyst Decision
  • MDWD Strong Buy
  • KEQU
  • Analyst Count
  • MDWD 1
  • KEQU 0
  • Target Price
  • MDWD $25.00
  • KEQU N/A
  • AVG Volume (30 Days)
  • MDWD 69.9K
  • KEQU 36.1K
  • Earning Date
  • MDWD 03-20-2025
  • KEQU 03-05-2025
  • Dividend Yield
  • MDWD N/A
  • KEQU N/A
  • EPS Growth
  • MDWD N/A
  • KEQU 168.79
  • EPS
  • MDWD N/A
  • KEQU 6.31
  • Revenue
  • MDWD $19,720,000.00
  • KEQU $199,637,000.00
  • Revenue This Year
  • MDWD $10.15
  • KEQU N/A
  • Revenue Next Year
  • MDWD $25.62
  • KEQU N/A
  • P/E Ratio
  • MDWD N/A
  • KEQU $9.66
  • Revenue Growth
  • MDWD N/A
  • KEQU N/A
  • 52 Week Low
  • MDWD $11.04
  • KEQU $27.00
  • 52 Week High
  • MDWD $24.00
  • KEQU $67.20
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 63.06
  • KEQU 60.08
  • Support Level
  • MDWD $17.47
  • KEQU $54.02
  • Resistance Level
  • MDWD $18.79
  • KEQU $65.83
  • Average True Range (ATR)
  • MDWD 1.06
  • KEQU 2.91
  • MACD
  • MDWD 0.14
  • KEQU -0.56
  • Stochastic Oscillator
  • MDWD 96.41
  • KEQU 58.59

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About KEQU Kewaunee Scientific Corporation

Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.

Share on Social Networks: